Lev Pharmaceuticals to Present at the BIO CEO & Investor Conference

NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) (OTCBB:LEVP.OB) announced today that Joshua Schein, Ph.D., Chief Executive Officer of Lev will present at the BIO CEO & Investor Conference 2008, being held February 11-13 at the Waldorf Astoria in New York City. Dr. Schein will present a corporate progress report, including an update on the Company’s lead product candidate, Cinryze™ (C1 inhibitor). The Lev presentation is scheduled to begin at 10:15 AM ET on Tuesday, February 12^th.

The Lev presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.levpharma.com. The 40-minute presentation will also be available on the Lev website in replay format for a limited time following the conference.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev’s lead product candidate, Cinryze™ (C1 inhibitor), is being developed as a replacement therapy for both the acute and prophylactic treatment of Hereditary Angioedema (HAE), also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

For more information about Lev, Cinryze (C1 inhibitor), or HAE, please contact Lev directly at 212-682-3096, or visit Lev’s website at www.levpharma.com.